Document is current
Any future updates will be listed below
-
Authors
Montoliu-Gaya, Laia https://orcid.org/0000-0001-7684-6318
Salvadó, Gemma https://orcid.org/0000-0002-5210-9230
Therriault, Joseph
Nilsson, Johanna https://orcid.org/0000-0002-2856-6060
Janelidze, Shorena https://orcid.org/0000-0003-2869-8378
Weiner, Sophia https://orcid.org/0009-0000-2298-220X
Ashton, Nicholas J.
Benedet, Andrea L.
Rahmouni, Nesrine
Lantero-Rodriguez, Juan https://orcid.org/0000-0002-7426-678X
Mattsson-Carlgren, Niklas https://orcid.org/0000-0002-8885-7724
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Brinkmalm, Gunnar https://orcid.org/0000-0001-6958-2393
Stomrud, Erik
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Gobom, Johan https://orcid.org/0000-0001-6193-6193
Rosa-Neto, Pedro https://orcid.org/0000-0001-9116-1376
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 29 July 2025
First Online: 22 August 2025
Competing interests
: L.M.-G. has received speaker fees from Quanterix and Esteve, and served as consultant for Quanterix. G.S. has received speaker fees from Springer Nature, Esteve, GE Healthcare and Adium and has participated in advisory board for Johnson & Johnson. H.Z. has served at scientific advisory boards and/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche and WebMD; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). S.P. has acquired research support (for the institution) from Avid and ki elements through ADDF. In the past 2 years, he has received consultancy/speaker fees from BioArtic, Biogen, Esai, Eli Lilly, Novo Nordisk and Roche. K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this Article. P.R.-N. participated in advisory board for Roche, Novo Nordisk and Cerveau (outside submitted work). O.H. is an employee of Eli Lilly and Lund University, and he has previously acquired research support (for Lund University) from Avid Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy/speaker fees from ALZpath, BioArctic, Biogen, Bristol Myers Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. J.T. has served as a paid consultant for Neurotorium and for Alzheon Inc. P.R.-N. participated in advisory board for Roche, Novo Nordisk and Cerveau (outside submitted work). N.M.-C. has received consultancy/speaker fees from Biogen, Merck and Owkin. The other authors declare no competing interests.
